Update on Parathyroid Carcinoma

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2016 Mar 23

PMID 27001435

Citations 49

Authors

F Cetani

E Pardi

C Marcocci

Affiliations

Soon will be listed here.

Abstract

Introduction: Parathyroid carcinoma (PC) is a rare endocrine disorder, commonly causing severe primary hyperparathyroidism (PHPT). PC is mainly a sporadic disease, but it may occur in familial PHPT. Patients with PC usually present markedly elevated serum calcium and PTH. The clinical features are mostly due to the effects of the excessive secretion of PTH rather than to the spread of tumor. At times, the diagnosis can be difficult.

Purpose: The aim of this work is to review the available data on PC, and focus its molecular pathogenesis and the clinical utility of CDC73 genetic testing and immunostaining of its product, parafibromin. The pathological diagnosis of PC is restricted to lesions showing unequivocal growth into adjacent tissues or metastasis. Inactivating mutations of the cell division cycle 73 (CDC73) gene have been identified in up to 70 % of apparently sporadic PC and in one-third are germline. Loss of parafibromin immunostaining has been shown in most PC. The association of CDC73 mutations and loss of parafibromin predicts a worse clinical outcome and a lower overall 5- and 10-year survival.

Conclusions: The treatment of choice is the en bloc resection of the tumor. The course of PC is variable; most patients have local recurrences or distant metastases and die from unmanageable hypercalcemia.

Citing Articles

PARATHYROID CARCINOMA WITH LACK OF CLINICAL SYMPTOMS: A CASE REPORT AND REVIEW OF LITERATURE.

Zhou R Acta Endocrinol (Buchar). 2024; 20(1):103-106.

PMID: 39372305 PMC: 11449241. DOI: 10.4183/aeb.2024.103.

Efficacy of surufatinib in the treatment of advanced parathyroid carcinoma: A case report.

Yu Z, Zhou J, Li F, Xie X, Hu L, Chen L Heliyon. 2024; 10(17):e36656.

PMID: 39319169 PMC: 11419863. DOI: 10.1016/j.heliyon.2024.e36656.

Incidental synchronous intrathyroidal parathyroid carcinomas and papillary thyroid microcarcinoma with compressive neck mass and primary hyperparathyroidism: case report and literature review.

Xu T, Zheng X, Wei T BMC Endocr Disord. 2024; 24(1):125.

PMID: 39054438 PMC: 11270972. DOI: 10.1186/s12902-024-01656-8.

Long-term survival in a patient with metastatic parathyroid carcinoma harboring an sensitizing mutation: a case report.

Ying Y, Li H, Xia W, Cheng T, Li H, Fu Q J Int Med Res. 2024; 52(7):3000605241259669.

PMID: 39053452 PMC: 11283662. DOI: 10.1177/03000605241259669.

Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature.

Katoh H, Mitsuma T, Okamoto R, Naito K, Tokito T, Kikuchi M Endocr J. 2024; 71(11):1069-1075.

PMID: 38987211 PMC: 11778383. DOI: 10.1507/endocrj.EJ24-0126.

References

Clayman G, Gonzalez H, El-Naggar A, Vassilopoulou-Sellin R . Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer. 2004; 100(5):900-5. DOI: 10.1002/cncr.20089. View

Hunter G, Schellingerhout D, Vu T, Perrier N, Hamberg L . Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology. 2012; 264(3):789-95. DOI: 10.1148/radiol.12110852. View

Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo L . Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992; 16(4):724-31. DOI: 10.1007/BF02067369. View

Enomoto K, Uchino S, Ito A, Watanabe S, Shibuya H, Enomoto Y . The surgical strategy and the molecular analysis of patients with parathyroid cancer. World J Surg. 2010; 34(11):2604-10. DOI: 10.1007/s00268-010-0618-x. View

Wynne A, van Heerden J, Carney J, Fitzpatrick L . Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992; 71(4):197-205. View

Cetani F, Pardi E, Borsari S, Marcocci C . Molecular pathogenesis of primary hyperparathyroidism. J Endocrinol Invest. 2011; 34(7 Suppl):35-9. View

Wassif W, Moniz C, Friedman E, Wong S, Weber G, Nordenskjold M . Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab. 1993; 77(6):1485-9. DOI: 10.1210/jcem.77.6.7903311. View

Witteveen J, Hamdy N, Dekkers O, Kievit J, van Wezel T, Teh B . Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol. 2011; 24(5):688-97. DOI: 10.1038/modpathol.2010.236. View

Whitson B, Broadie T . Preoperative ultrasound and nuclear medicine studies improve the accuracy in localization of adenoma in hyperparathyroidism. Surg Today. 2008; 38(3):222-6. DOI: 10.1007/s00595-007-3612-7. View

10.

Carpten J, ROBBINS C, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J . HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002; 32(4):676-80. DOI: 10.1038/ng1048. View

11.

Domingues R, Tomaz R, Martins C, Nunes C, Bugalho M, Cavaco B . Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2011; 76(1):33-8. DOI: 10.1111/j.1365-2265.2011.04184.x. View

12.

Betea D, Bradwell A, Harvey T, Mead G, Schmidt-Gayk H, Ghaye B . Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004; 89(7):3413-20. DOI: 10.1210/jc.2003-031911. View

13.

Newey P, Bowl M, Cranston T, Thakker R . Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010; 31(3):295-307. DOI: 10.1002/humu.21188. View

14.

Hahn M, Marsh D . Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett. 2007; 581(26):5070-4. DOI: 10.1016/j.febslet.2007.09.050. View

15.

Shifrin A, LiVolsi V, Shifrin-Douglas S, Zheng M, Erler B, Matulewicz T . Primary and metastatic parathyroid malignancies: a rare or underdiagnosed condition?. J Clin Endocrinol Metab. 2014; 100(3):E478-81. DOI: 10.1210/jc.2014-2760. View

16.

Costa-Guda J, Imanishi Y, Palanisamy N, Kawamata N, Koeffler H, Chaganti R . Allelic imbalance in sporadic parathyroid carcinoma and evidence for its de novo origins. Endocrine. 2013; 44(2):489-95. PMC: 3683451. DOI: 10.1007/s12020-013-9903-4. View

17.

Verdelli C, Forno I, Vaira V, Corbetta S . MicroRNA deregulation in parathyroid tumours suggests an embryonic signature. J Endocrinol Invest. 2015; 38(4):383-8. DOI: 10.1007/s40618-014-0234-y. View

18.

Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S . Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest. 2008; 31(10):900-4. PMC: 5319599. DOI: 10.1007/BF03346439. View

19.

Evangelista L, Sorgato N, Torresan F, Merante Boschin I, Pennelli G, Saladini G . FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol. 2011; 2(10):348-54. PMC: 3191327. DOI: 10.5306/wjco.v2.i10.348. View

20.

DeLellis R . Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma. Endocr Pathol. 2008; 19(4):221-5. DOI: 10.1007/s12022-008-9050-2. View